Cue Biopharma, Inc. (CUE) vs Organogenesis Holdings Inc. (ORGO)
A side-by-side comparison of Cue Biopharma, Inc. and Organogenesis Holdings Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CUE
Cue Biopharma, Inc.
$24.25HealthcareDelayed quote: Oct 6, 2026, 11:28 AM EDT
ORGO
Organogenesis Holdings Inc.
$1.32HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Total return — CUE vs ORGO
growth of $100 · dividends reinvested · last 9yCUE -93.0% (-25.6%/yr)ORGO -87.0% (-20.3%/yr)ORGO compounded faster over this window
CUE ORGO
CUE vs ORGO: by the numbers
- •CUE is the larger company ($176M vs $169M market cap).
- •Both run net losses; ORGO's is the smaller (-19.76% vs -435.83% net margin).
- •CUE grew revenue faster over the past five years (47.08% vs 1.05% CAGR).
Metrics side by side
Valuation
| Metric | CUE | ORGO |
|---|---|---|
| P/S ratio | 4.68 | 0.37 |
| P/B ratio | 76.26 | 1.14 |
| EV / EBITDA | N/A | 213.31 |
| FCF yield | N/A | 12.32% |
Profitability
| Metric | CUE | ORGO |
|---|---|---|
| Gross margin | 99.69% | 67.59% |
| Operating margin | -96.56% | 9.92% |
| Net margin | -435.83% | -19.76% |
| ROE | -7104.24% | -31.32% |
| ROIC | -1039.56% | -8.34% |
Growth (annualized)
| Metric | CUE | ORGO |
|---|---|---|
| Revenue CAGR (5Y) | 47.08% | 1.05% |
| FCF CAGR (5Y) | N/A | -5.54% |
| Total return CAGR (5Y) | -42.42% | -37.41% |
Frequently asked
- Which has grown faster, CUE or ORGO?
- Over the past five years, CUE grew revenue faster — CUE at a 47.08% CAGR versus ORGO at 1.05%.
- How have CUE and ORGO total returns compared?
- Over the past 5 years, CUE delivered -42.42% and ORGO delivered -37.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cue Biopharma ROEOrganogenesis ROECue Biopharma operating marginOrganogenesis operating marginCue Biopharma revenue growthOrganogenesis revenue growthCue Biopharma free cash flowOrganogenesis free cash flow
Cue Biopharma & Organogenesis appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.